Trial Profile

Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma: a Prospective Multi-center Phase II Study

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Orelabrutinib (Primary) ; Sintilimab (Primary) ; Tislelizumab (Primary)
Indications CNS cancer; Intraocular lymphoma; Lymphoma
Focus Therapeutic Use

Most Recent Events

17 Jun 2022 Results (at data cut-off date 25 Feb 2022; n=13) presented at the 27th Congress of the European Haematology Association.
27 May 2021 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com